Why did Apollo Endosurgery, Inc. (APEN) shares slip in the Pre-marketing session?

ASTR Stock
ASTR Stock

Apollo Endosurgery, Inc. (NASDAQ: APEN), shares dropped -4.28% to 3.800 in the early morning today as the global leader in minimally invasive surgical methods announced that the X-Tack Endoscopic HeliX Tacking System had received 510(k) clearance from the U.S. Food & Drug Administration.

The X-Tack is a brand new through-the-scope, a suture-based device designed specifically to treat gastrointestinal problems in the lower gastrointestinal tract with applications in the upper gastrointestinal tract.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Read More

X-Tack allows physicians to solve challenges commonly encountered when closing irregularly shaped or large defects. This procedure involves suture-tethered HeliX tacks, positioned independently in adjacent healthy tissue, and are then cinched to close the construct. The X-Tack system answers a long-expressed need for advanced closure devices to improve healing and prevent adverse events after colonic polypectomy and mucosal resections, such as delayed bleeding or perforation.

A limited launch with gastroenterologists will be initiated in January 2021 to be followed by a full launch late in the first quarter of 2021.


Please enter your comment!
Please enter your name here